Faculty of Health Sciences, Simon Fraser University, Blusson Hall, Room 11300, 8888 University Drive, Burnaby, BC, V5A 1S6, Canada.
British Columbia Centre on Substance Use, Providence Health Care, 400-1045 Howe St, Vancouver, BC, V6Z 2A9, Canada.
Subst Abuse Treat Prev Policy. 2018 Nov 27;13(1):41. doi: 10.1186/s13011-018-0180-3.
BACKGROUND: Nonmedical prescription opioid use (NMPOU) is a serious public health problem in North America. At a population-level, previous research has identified differences in the prevalence and correlates of NMPOU among younger versus older age groups; however, less is known about age-related differences in NMPOU among people who use illegal drugs. METHODS: Data were collected between 2013 and 2015 from two linked prospective cohort studies in Vancouver, Canada: the At-Risk Youth Study (ARYS) and the Vancouver Injection Drug Users Study (VIDUS). Factors independently associated with NMPOU among younger (ARYS) and older (VIDUS) participants were examined separately using bivariate and multivariate generalized estimating equations. RESULTS: A total of 1162 participants were included. Among 405 eligible younger participants (Median age = 25; Inter-Quartile Range [IQR]: 22-28), 40% (n = 160) reported engaging in NMPOU at baseline; among 757 older participants (Median age = 48, IQR: 40-55), 35% (n = 262) reported engaging in NMPOU at baseline. In separate multivariate analyses of younger and older participants, NMPOU was positively and independently associated with heroin use (younger: Adjusted Odds Ratio [AOR] = 3.12, 95% Confidence Interval [CI]: 2.08-4.68; older: AOR = 2.79, 95% CI: 2.08-3.74), drug dealing (younger: AOR = 2.22, 95% CI: 1.58-3.13; older: AOR = 1.87, 95% CI: 1.40-2.49), and difficulty accessing services (younger: AOR = 1.47, 95% CI: 1.04-2.09; older: AOR = 1.74, 95% CI: 1.32-2.29). Among the youth cohort only, NMPOU was associated with younger age (AOR = 1.12, 95% CI: 1.05-1.19), crack use (AOR = 1.56, 95% CI: 1.06-2.30), and binge drug use (AOR = 1.41, 95% CI: 1.00-1.97); older participants who engaged in NMPOU were more likely to report crystal methamphetamine use (AOR = 1.97, 95% CI: 1.46-2.66), non-fatal overdose (AOR = 1.76, 95% CI: 1.20-2.60) and sex work (AOR = 1.49, 95% CI: 1.00-2.22). DISCUSSION: The prevalence of NMPOU is similar among younger and older people who use drugs, and independently associated with markers of vulnerability among both age groups. Adults who engage in NMPOU are at risk for non-fatal overdose, which highlights the need for youth and adult-specific strategies to address NMPOU that include better access to health and social services, as well as a range of addiction treatment options for opioid use. Findings also underscore the importance of improving pain treatment strategies tailored for PWUD.
背景:非医疗处方阿片类药物使用(NMPOU)是北美的一个严重公共卫生问题。在人群层面上,以前的研究已经确定了年轻和年长人群中 NMPOU 的流行率和相关因素存在差异;然而,对于吸毒者中与年龄相关的 NMPOU 差异知之甚少。
方法:数据来自加拿大温哥华的两项前瞻性队列研究:危险青年研究(ARYS)和温哥华注射吸毒者研究(VIDUS),于 2013 年至 2015 年期间收集。使用双变量和多变量广义估计方程分别检查年轻(ARYS)和年长(VIDUS)参与者中与 NMPOU 独立相关的因素。
结果:共纳入 1162 名参与者。在 405 名符合条件的年轻参与者中(中位年龄 25 岁;四分位距[IQR]:22-28),40%(n=160)报告在基线时存在 NMPOU;在 757 名年长参与者中(中位年龄 48 岁,IQR:40-55),35%(n=262)报告在基线时存在 NMPOU。在对年轻和年长参与者的单独多变量分析中,NMPOU 与海洛因使用呈正相关且独立相关(年轻:调整后的优势比[AOR] = 3.12,95%置信区间[CI]:2.08-4.68;年长:AOR = 2.79,95% CI:2.08-3.74)、毒品交易(年轻:AOR = 2.22,95% CI:1.58-3.13;年长:AOR = 1.87,95% CI:1.40-2.49)和难以获得服务(年轻:AOR = 1.47,95% CI:1.04-2.09;年长:AOR = 1.74,95% CI:1.32-2.29)。仅在青年队列中,NMPOU 与年龄较小(AOR = 1.12,95% CI:1.05-1.19)、可卡因使用(AOR = 1.56,95% CI:1.06-2.30)和药物滥用(AOR = 1.41,95% CI:1.00-1.97)相关;参与 NMPOU 的年长参与者更有可能报告使用冰毒(AOR = 1.97,95% CI:1.46-2.66)、非致命性过量(AOR = 1.76,95% CI:1.20-2.60)和性工作(AOR = 1.49,95% CI:1.00-2.22)。
讨论:在使用毒品的年轻和年长人群中,NMPOU 的流行率相似,并且与两个年龄组的脆弱性指标独立相关。参与 NMPOU 的成年人有非致命性过量的风险,这突显了需要针对年轻人和成年人制定特定的策略来解决 NMPOU 问题,包括更好地获得健康和社会服务,以及一系列针对阿片类药物使用的成瘾治疗选择。研究结果还强调了改进针对吸毒者的疼痛治疗策略的重要性。
Subst Abuse Treat Prev Policy. 2018-11-27
Subst Abuse Treat Prev Policy. 2018-7-5
Subst Abuse Treat Prev Policy. 2017-5-30
J Subst Use Addict Treat. 2023-5
Health Rep. 2021-3-17
BMC Public Health. 2020-7-9
Subst Abuse Treat Prev Policy. 2018-5-22
Int J Drug Policy. 2017-12-8
Can J Public Health. 2017-11-9
Int J Drug Policy. 2017-8